title: [Angiotensin II receptor blockers (ARBs) and cancer: a reassuring balance].
abstract: The effects of drugs on new cancer and cancer-related death are a major concern. Recently, a meta-analysis raised the possibility that ARBs might have an adverse impact in this respect. This point of view was highly debated until the publication of two other meta-analyses which did not demonstrate any increased risk of new cancer occurrence as well as of cancer related-death with the use of ARBs in patients with hypertension, heart failure and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically in order to avoid biased conclusions. Overall the bulk of evidence today indicates that ARBs are not associated with an increased cancer risk.
authors.affiliation: Division de physiopathologie clinique, CHUV, 1011 Lausanne.
authors.forename: M
authors.initials: M
authors.lastname: Cassat
authors.forename: G
authors.initials: G
authors.lastname: Wuerzner
authors.forename: M
authors.initials: M
authors.lastname: Burnier
authors.forename: B
authors.initials: B
authors.lastname: Waeber
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000139:chemically induced; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists